Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 2/20 | 0.38 |
| ▸ | STAT3 | P40763 | 3/20 | 0.38 |
| ▸ | SYNJ2 | O15056 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15173027 | 0.81 | SYNJ2 (0.39) | PTPN1STAT3SYNJ2MAPT | |
| Isozaluzanin C SCHEMBL17214374 | 0.73 | PKM (0.40) | MAPT | |
| SCHEMBL29785300 | 0.72 | SLC5A1 (0.35) | PTPN1MAPTSLC6A2KDM4E | |
| Vernoflexin SCHEMBL31570936 | 0.71 | NLRP3 (0.35) | — | |
| SCHEMBL31465656 | 0.68 | CYP19A1 (0.44) | STAT3 | |
| Dehydrocostuslactone SCHEMBL31029489 | 0.66 | CYP19A1 (0.46) | MAPT | |
| Dehydrocostuslactone SCHEMBL699070 | 0.66 | CYP19A1 (0.46) | MAPT | |
| SCHEMBL29425906 | 0.65 | STAT3 (0.49) | PTPN1STAT3MAPT | |
| SCHEMBL31395402 | 0.64 | NLRP3 (0.54) | — | |
| SCHEMBL28121333 | 0.63 | PTPN1 (0.56) | PTPN1STAT3SYNJ2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118987012-A | Application of compound Glucozaluzanin C in Ainsliaea fragrans champ in preparation of medicaments for treating hepatitis | 江西中医药大学 | 2024-11-22 | — | — | CN | claimed |
| CN-118987012-A | Application of compound Glucozaluzanin C in Ainsliaea fragrans champ in preparation of medicaments for treating hepatitis | 江西中医药大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118987012-A | Application of compound Glucozaluzanin C in Ainsliaea fragrans champ in preparation of medicaments for treating hepatitis | 江西中医药大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118987012-A | Application of compound Glucozaluzanin C in Ainsliaea fragrans champ in preparation of medicaments for treating hepatitis | 江西中医药大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-107417744-A | A kind of sucrose derivative and preparation method thereof and the purposes as cancer therapy drug | 中国人民解放军第二军医大学 | 2017-12-01 | — | — | CN | disclosed |
| CN-102112427-B | Novel diaryl hepatonoid-based compound and use thereof | RNL BIO CO LTD | 2013-11-13 | — | — | CN | disclosed |
| US-8426370-B2 | Diaryl hepatonoid-based compounds and use thereof | RNL BIO CO., LTD. (KR) | 2013-04-23 | — | — | US | disclosed |
| CN-102112427-A | Novel diaryl hepatonoid-based compound and use thereof | RNL BIO CO LTD | 2011-06-29 | — | — | CN | disclosed |
| US-20110124740-A1 | NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF | RNL BIO CO., LTD. (KR) | 2011-05-26 | — | — | US | disclosed |
| US-20110105738-A1 | DIARYL HEPATONOID-BASED COMPOUNDS USEFUL AS VIRUS INHIBITORS | RNL BIO CO., LTD. (KR) | 2011-05-05 | — | — | US | disclosed |
| US-20110098261-A1 | TRITERPENOID-BASED COMPOUNDS USEFUL AS VIRUS INHIBITORS | RNL BIO CO., LTD. (KR) | 2011-04-28 | — | — | US | disclosed |
| US-20110098239-A1 | NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF | RNL BIO CO., LTD. (KR) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105738-A1 | DIARYL HEPATONOID-BASED COMPOUNDS USEFUL AS VIRUS INHIBITORS | HAVCR2, CYP7A1, CYP51A1 | PTPN1 1294/4885STAT3 4308/4885SYNJ2 2712/4885 |
| US-20110098239-A1 | NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF | HAVCR2, SLC10A1, CYP7A1 | PTPN1 585/4885STAT3 2552/4885SYNJ2 3077/4885 |
| US-20110124740-A1 | NOVEL DIARYL HEPATONOID-BASED COMPOUNDS AND USE THEREOF | HAVCR2, SLC10A1, HSD11B1 | PTPN1 565/4885STAT3 2688/4885SYNJ2 3165/4885 |
| US-20110098261-A1 | TRITERPENOID-BASED COMPOUNDS USEFUL AS VIRUS INHIBITORS | ZC3HAV1, CYP51A1, ZC3HAV1L | PTPN1 2443/4885STAT3 2171/4885SYNJ2 2762/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.